Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


Early Release

  • Vital Signs: National and State-Specific Patterns of Attention Deficit/Hyperactivity Disorder Treatment Among Insured Children Aged 2–5 Years — United States, 2008–2014

    	The figure above is a photograph showing a girl and a boy.MAY 3, 2016
    The American Academy of Pediatrics 2011 guidelines recommend “behavior therapy” over medication as first-line treatment for children aged 4–5 years with attention deficit/hyperactivity disorder (ADHD). CDC analyzed Medicaid and employer-sponsored insurance (ESI) claims to assess national and state-level ADHD treatment patterns among young children. Among insured children aged 2–5 years receiving clinical care for ADHD, medication treatment was more common than receipt of recommended first-line treatment with psychological services. Among children with ADHD who had ESI, receipt of psychological services did not increase after release of the 2011 guidelines.

  • Update: Ongoing Zika Virus Transmission — Puerto Rico, November 1, 2015–April 14, 2016

    APRIL 29, 2016
    During November 1, 2015–April 14, 2016, a total of 6,157 specimens from suspected Zika virus–infected patients from Puerto Rico were evaluated, and 683 (11%) had laboratory evidence of current or recent Zika virus infection. Of the 683, there were 65 (10%) symptomatic pregnant women who tested positive for Zika. A total of 17 (2%) patients required hospitalization, including five patients with suspected Guillain-Barré syndrome. One patient died after developing severe thrombocytopenia. The public health response in Puerto Rico includes increased capacity to test for Zika virus, preventing infection in pregnant women, monitoring infected pregnant women and their fetus for adverse outcomes, controlling mosquitos, and assuring the safety of blood products.

Current Weekly


Surveillance Summaries

Recommendations and Reports

  • CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016

    MARCH 18, 2016
    This guideline provides recommendations for primary care providers who are prescribing opioids for chronic pain outside of active cancer treatment, palliative care, and end-of-life care. The guideline addresses 1) when to initiate or continue opioids for chronic pain; 2) opioid selection, dosage, duration, follow-up, and discontinuation; and 3) assessing risk and addressing harms of opioid use. This guideline is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including abuse, dependence, overdose, and death.


  • Development of the Community Health Improvement Navigator Database of Interventions

    FEBRUARY 26, 2016
    This report describes the development of the database of interventions included in the Community Health Improvement Navigator, released by CDC in 2015. The database allows the user to easily search for multisector, collaborative, evidence-based interventions to address the underlying causes of the greatest morbidity and mortality in the United States: tobacco use and exposure, physical inactivity, unhealthy diet, high cholesterol, high blood pressure, diabetes, and obesity. Hospital administrators can use the CHI Navigator’s database of interventions to select and implement evidence-based interventions that have been effective in similar communities with similar collaborators to develop plans to address problems identified in the triennial community health needs assessment, in alignment with the IRS requirements for tax-exempt status.

Notifiable Diseases